Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

1998 ◽  
Vol 47 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Timothy Edward Kute ◽  
Jan Grøndahl-Hansen ◽  
Si-Ming Shao ◽  
Rena Long ◽  
Greg Russell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Cathepsin D ◽  
Low Risk ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Risk Of Recurrence ◽  
Node Negative Breast Cancer

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 525-525 ◽  
Author(s):  
S. Maier ◽  
I. Nimmrich ◽  
A. Marx ◽  
S. Eppenberger-Castori ◽  
F. Jaenicke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Methylation Profile ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Risk Of Recurrence ◽  
Node Negative Breast Cancer ◽  
Dna Methylation Profile

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 525-525
Author(s):  
S. Maier ◽  
I. Nimmrich ◽  
A. Marx ◽  
S. Eppenberger-Castori ◽  
F. Jaenicke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Methylation Profile ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Risk Of Recurrence ◽  
Node Negative Breast Cancer ◽  
Dna Methylation Profile

scholarly journals Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis

1997 ◽  
Vol 76 (5) ◽  
pp. 661-666 ◽  
Author(s):  
G Ferrandina ◽  
G Scambia ◽  
F Bardelli ◽  
P Benedetti Panici ◽  
S Mancuso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cathepsin D ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Disease Free

scholarly journals Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies

2002 ◽  
Vol 48 (8) ◽  
pp. 1194-1197 ◽  
Author(s):  
Michael J Duffy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Poor Prognosis ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Level 1 ◽  
Pai 1

Abstract Background: For optimum management of patients with cancer, accurate assessment of prognosis is essential. The primary determinant of outcome in malignancy is the formation of distant metastases. Urokinase plasminogen activator (uPA) is a serine protease causally involved in invasion and metastasis. Content: Data from model systems show that uPA is unequivocally involved in cancer dissemination. Consistent with its role in metastasis, multiple independent groups have shown that high uPA concentrations in primary breast cancers correlate with poor prognosis. For determining outcome, the prognostic impact of uPA was both independent of traditionally used factors and prognostic in patients with axillary node-negative disease. Paradoxically, high concentrations of plasminogen activator inhibitor (PAI-1), an endogenous inhibitor of uPA, also correlate with poor prognosis in patients with breast cancer, including the subgroup with node-negative disease. The prognostic value of uPA/PAI-1 in axillary node-negative breast cancer patients was recently confirmed in both a prospective randomized trial and a pooled analysis, i.e., two different level 1 evidence (LOE-1) studies. Conclusions: uPA and PAI-1 are among the first biological prognostic factors to have their clinical value validated using LOE-1 evidence studies. Determination of these analytes may help identify low-risk node-negative breast cancer patients for whom adjuvant chemotherapy is unnecessary.

K167: is it a prognostic index in node negative breast cancer patients?

2001 ◽  
Vol 37 ◽  
pp. S121
Author(s):  
F. Valcamonico ◽  
G. Grigolato ◽  
F. Donato ◽  
V.D. Ferrari ◽  
E. Simoncini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Index ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document